Ocuphire Pharma, Inc. OCUP · Stock Open Ocuphire Pharma, Inc. in new tab
Ocuphire Pharma, Inc. Analysis (OCUP)
Is Ocuphire Pharma, Inc. a good investment? Ocuphire Pharma, Inc. (OCUP) is currently trading at 1.17 USD.
Investor FAQ
Does Ocuphire Pharma, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Ocuphire Pharma, Inc.?
Ocuphire Pharma, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
Company Profile
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
Community Discussion